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Abstract:
Background: Breast cancers metastasizing to thyroid gland are relatively uncommon in clinical practice.
Objective: Retrospective analysis of  data from breast cancer patients with thyroid metastasis (TM).
Methods: The US suspected, fine-needle aspiration cytology (FNAC) confirmed TM in breast cancer patients, treated 
between 2005 and 2015 at our hospital, was retrospectively analyzed. The data were re-evaluated by the pathologist 
and radiologist who were blinded to the patients’ data.
Results: FNAC and immunohistochemistry confirmed the ultrasonography (US) suspected TM in eight breast cancer 
patients. Clinically both unilateral and bilateral TM was seen, which were symptomless and metachronously (6-121 
months) metastasized. Six of  eight cases exhibited recurrence/distant metastasis and were treated with chemother-
apy/thyroidectomy of  which two cases passed away. The remaining two patients had no recurrences/distant metas-
tases and were treated with partial/total thyroidectomy. Post-chemotherapy US showed more homogenous thyroid 
parenchyma with gathering of  calcification that reduced in size, revealing the sensitiveness of  TM to chemotherapy.
Conclusion: US was useful in screening TM in breast cancer patients. Both partial and total thyroidectomy was effec-
tive in disease free survival of  isolated TM cases, with controlled primary condition. TM responded well to chemo-
therapy in most of  the recurrent breast cancer cases with or without distant metastasis.
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Introduction
Breast cancer is the leading cause of  cancer related death 
in women. In spite of  its relatively early detection and 
treatment, distant metastasis to various tissues, including 
thyroid gland, still remains a challenge. In general, despite 
its high vascularization, metastasis to thyroid gland is un-
common (incidence of  0-5% in non-malignant cases to 
about 24% in malignant cases) and mostly metachronous, 
as reported in series of  autopsy studies.1-7 Metachro-
nous thyroid metastasis is defined as thyroid metastasis 
observed at or greater than 6 months after the diagno-
sis of  primary cancer. Following the pattern, reports of  
breast cancer metastasizing to thyroid gland are relatively 
uncommon in clinical practice too; however, breast car-
cinoma is one of  the common primary tumor of  thyroid 
metastasis, seen at post-mortem.8 With this rarity, added 
with metachronous metastasis nature, particularly many 
years after the diagnosis of  initial tumor, can pose a di-
agnostic challenge. Also, as treatment strategies used to 
treat primary and metastatic thyroid malignancies vary, 
it becomes essential to appropriately distinguish prima-
ry thyroid cancer from metastatic thyroid cancer. In this 
regard, routine US assessment of  thyroid gland, followed 
by FNAC on suspicion, is part of  the breast cancer pa-
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tients’ diagnostic regimen in our hospital through which 
TM patients are identified. The objective of  present study 
was to analyze the ultrasonographic and clinical features 
of  TM condition in breast cancer patients, through which 




The study was approved by our hospital ethics commit-
tee, reference number - IRB-2015-243, who waived  the 
need for informed consent procedure. All the patients’ 
personal identification information was removed before 
study related usage.
Patients
Between 2005 and 2015, routine US analysis of  breast 
cancer patients revealed seven cases with radiograph-
ic changes in their thyroid architecture, who underwent 
US-guided fine-needle aspiration cytology (FNAC) con-
firming TM. The US-guided FNAC was performed using 
a 5ml syringe, with 1~2ml negative press, targeting the 
region that seemed to show the most compact area of  so-
nographically visible microcalcifications or nodules, and 
thus suspicious for malignancy. An eighth case of  TM, 
diagnosed and treated at a different hospital, visited our 
hospital for follow up, whose data we also considered in 
this analysis.
Conventional US
The obtained conventional US reports of  all patients 
were performed using the wide-band 5-10 MHz linear 
probe on a single ultrasound machine (Philips IU22, 
Philips Medical System, Bothell, WA, USA) by three dif-
ferent radiologists with over eight years of  experience. 
The high-resolution images were documented/stored in 
PACS system.
For the study purpose, to reduce the inter-observer vari-
ability, all the images were retrospectively reviewed by a 
radiologist (>15 years of  experience) who was blinded 
to the clinical, radiological and pathological findings. The 
US findings were assessed for: echogenicity of  thyroid 
parenchyma, the appearance of  the lesions (with mass or 
without mass), mass details (size, contour, margin, echo-
genicity, internal structure and vascularity) and presence 
of  calcification. Any discrepancy was resolved through 
discussion with the respective radiologist who provided 
the prior diagnosis.
Tissue processing and analysis:
Smear slides, prepared from the thyroid gland aspirate, 
were subject to histological [hematoxylin and eosin 
(H&E) stain] and immunohistochemical [thyroglobulin 
(TG) and thyroid transcription factor – 1 (TTF-1)] anal-
ysis. FNAC was also performed for “recurrent foci at 
chest wall” which served as a reference standard for cel-
lular morphological assessments. In addition to the above 
stains, the thyroid tissue samples obtained from thyroid-
ectomy in 2 patients were subject to immunohistochemi-
cal analysis for estrogen receptor (ER) and Progesterone 
receptor (PR). The slides were read by two qualified and 
experienced (>25 years) pathologists providing their di-
agnosis. For the study purpose, the H&E and immuno-
histochemistry images of  all the cases were re-read by a 
pathologist (>11 years of  experience) who was blinded to 
the prior diagnosis and other patient data. Any discrep-
ancy was resolved through discussion with the respective 
pathologist who provided the prior diagnosis. Clinical re-
cords of  all the patients were further analyzed for details 
of  the primary condition, interval between primary con-
dition diagnosis and TM, serum thyroid hormone level, 
primary pathology, other associated metastasis, therapeu-
tic strategy undertaken, and survival time after diagnosis.
Results
Clinical findings
The study comprised of  8 female patients who were 
diagnosed with  TM from breast cancer between 2005 
and 2015. The mean age at the diagnosis of  TM was 
55.37±9.33 years (range of  43 to 69 years). In all the 
subjects, the condition was symptomless at the time of  
diagnosis and was suspected of  TM during routine US 
examination.
Clinically, all the subjects had a history of  breast cancer 
and had received treatment for the same. Clinical details 
of  the primary condition are detailed under table 1. 
The location of  breast cancer of  these 8 cases was as 
follows: right (n=5), left (n=1) and bilateral (n=2). The 
median interval from the diagnosis of  breast cancer 
to detection of  TM was 76.5 months (range - 6 to 121 
months), and thus was labelled as “metachronous metas-
tasis” in all the cases. The details of  recurrence/distant 
metastasis associated with TM, the timeline at which they 
were diagnosed in respect to TM and their treatment reg-
imen are detailed in table 2.
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Briefly, two patients  presented with recurrence of  the 
primary condition on the chest wall and were treated 
with chemotherapy. Four patients exhibited associated 
metastasis to other organs/tissues, such as the lungs and 
lymph nodes (supraclavicular, axillary, cervical and me-
diastinal lymph nodes). Three of  these patients received 
chemotherapy while one underwent thyroidectomy (at a 
different hospital) for suspected malignant nodule. The 
remaining two patients (25%) showed no signs of  recur-
rence or distant metastasis and were treated with partial 
thyroidectomy (right lobectomy) for one case and total 
thyroidectomy for the other. One patient, who showed 
distant metastases to cervical and mediastinal lymph 
nodes, also presented with a history of  hyperthyroidism 




The survival time of  patients was considered from the 
date of  their TM diagnosis to the completion of  this 
study or till the patient died , whichever happened earlier 
(table 2). Two recurrence patients with foci on the chest 
wall received chemotherapy and were alive at 14 and 5 
months, respectively, from the date of  their TM diagno-
sis. Of  the four patients who exhibited distant metastasis, 
3 received chemotherapy of  which one patient died at 21 
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1 48 Bilateral 87 chest wall 
thyroid metastasis was 
diagnosed 20 months 
later than recurrence 
founded 






2 59 Right 27 chest wall 
thyroid metastasis was 
diagnosed 11 months 
later than recurrence 
founded 






3 57 Right 108 
Supraclavicular 
nodes, lung 
thyroid metastasis and 
recurrence 
was diagnosed at the 
same time  






4 67 Bilateral 71 Axilla nodes 
thyroid metastasis and 
recurrence was 
diagnosed at the same 
time 
heterogeneous and diffuse 
calcifications without 
nodule chemotherapy 
4(follow up  time is not 
long enough and we can 




5 48 Left 121 Lung 
lung metastasis was 
found after 
thyroidectomy 





6 52 Right 6 Nil 
No recurrence when 
thyroid metastasis was 
diagnosed 
hypoechoic solid nodular 
and nodular goiter Right lobectomy 
NA 
45 Alive 
7 69 Right 57 Nil 
No recurrence when 
thyroid metastasis was 
diagnosed 











thyroid metastasis was 
diagnosed 3months after 
the recurrence 
Typical Hyperthyroidism 






months while the remaining two were alive at 4 and 30 
months. One of  these four distant metastasis patients un-
derwent total thyroidectomy (at a different hospital) with 
no chemotherapy and died  at 15 months post-TM diag-
nosis. The remaining two patients with isolated TM had 
post-thyroidectomy disease free survival at 45 months 
(right lobectomy) and 38 months (total thyroidectomy), 
respectively, of  their TM diagnosis.
Histology/immunohistochemistry:
The diagnosis from the study specific pathologist was 
in agreement with the patients’ original histopathologi-
cal diagnosis. Microscopic examination of  H&E stained 
FNAC samples from thyroid aspirate revealed increased 
cellularity with clusters of  malignant epithelial cells (Fig 
1 A&B). 
The cells were highly pleomorphic with increased Nucle-
us/Cytoplasm (N/C) ratio, vesicular nuclear chromatin 
with prominent nucleoli and abundant cytoplasm. The 
characteristic features of  primary thyroid carcinoma, in-
cluding papillary formation, nuclear grove and intranu-
clear pseudoinclusion, were absent. Also all the samples 
were found TG and TTF-1 negative revealing malignant 
cells of  non-thyroid origin. The cellular morphology of  
all the FNAC samples matched to that of  the malignant 
cells found in the aspirate from “recurrent foci on the 
chest wall” thus confirming the primary source of  origin 
(Fig 1 C&D). 
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Immunohistochemical analysis of  thyroid tissue samples, 
obtained during thyroidectomy, showed ER positive cells 
in one sample and PR positive in the other, reconfirming 
the presence of  malignant breast epithelial cells (Fig 2).
 
Fig 1. A&B. H&E stained FNAC smear samples of thyroid aspirate showing 
highly cellular smear with clusters of malignant epithelial cells, C&D. H&E 
stained FNAC smear samples of aspirate from “recurrent foci on chest wall” 
showing malignant epithelial cells. 
 
 
Fig 2. Immunohistochemistry of thyroid tissue samples,  
obtained during thyroidectomy, showing ER positive cells (A)  
in one sample and PR positive (B) in the other 
A B
US features of  thyroid metastases in breast cancer 
patients                                      
The readings from the study specific radiologist agreed 
with the patients’ original radiological findings. US imag-
es of  six of  eight patients showed heterogeneous thyroid 
parenchyma with diffuse calcifications (Fig 3A). Five of  
these six patients showed no signs of  nodules while one 
showed a hyperthyroidism associated nodule. Post-che-
motherapy, the diffuse calcifications reduced and thyroid 
parenchyma appeared homogeneous in all the six patients 
(Fig 3B). The remaining two of  eight patients showed hy-
poechoic solid node, with irregular margins and multical-
cifications (Fig 3C), and one of  them was comorbid with 
nodular goiter. US and clinical findings of  all the eight 
patients are listed in table 2.
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Fig 3. A. Heterogeneous appearance with diffuse calcifications of the thyroid parenchyma, B. 
reduction in the calcification with homogeneous appearance of thyroid parenchyma 
after chemotheraphy, C. hypoechoic solid node with irregular margins and multicalcifications 
Discussion
The thyroid gland has an affluent blood supply of  about 
560 mL/100 g tissue/min, which is second only to the 
adrenal gland. Yet, thyroid metastasis from the cancer 
of  extra-thyroid origin is infrequent,9 and the reason for 
this  is not clear. Chung et al., found that the abnormal 
thyroid conditions like goiter increases the probability of  
TM, which may be due to alteration in local homeostasis 
resulting in decreased oxygen and iodine content.7,10,11 In 
the present study, 2/8 cases showed such associated thy-
roid pathology; goiter and hyperthyroidism. 
 
TM is usually observed in elderly individuals in their sixth 
and seventh decades of  life.12,13 Data from the present 
study revealed a mean age of  55.4 years which is slightly 
younger than that presented in the literature. As per au-
topsy reports, the incidence of  TM in patients who die as 
a result of  malignancy is up to 24%.14 The prevalence of  
thyroid nodules ranges from 20-67%, and the incidence 
of  malignant nodules is about 0.45–13%.15 In recent years 
the reports of  TM cases has been gradually increasing, 
which may be related to more frequent thyroid imaging 
and FNAC studies in cancer patients.16-18
 
Most common sites of  primary tumors are renal cell car-
cinoma, breast cancer and lung cancer, however, there 
is no complete agreement as to which cancer most fre-
quently metastasize to the thyroid as it may depend on 
many factors such as epidemiology and clinical behavior 
of  the primary cancer and diagnostic methods used.8 TM 
from renal cell carcinoma is usually symptomatic, where 
the patients present with symptoms such as a new neck 
mass, dysphagia and hoarseness, while that from lung and 
breast cancer may go symptomless.8 A study described an 
unusual case of  thyroid metastasis from breast carcino-
ma, characterized by massive intra-arterial embolization 
and clinically presented as acute thyroiditis, which is un-
common.19 Also TM can present as a synchronous orme-
tachronous manifestation of  known primary tumors or a 
first finding of  unknown primary tumor (occult primary 
neoplasm).20-23 All TM patients in our study were symp-
tomless, demonstrated metachronous metastasis, and 
were discovered during routine US imaging procedures. 
Several studies have assessed the usefulness of  US in pre-
dicting thyroid cancer, while characterizing its features, 
and recommend US evaluation as a good modality for 
early detection of  thyroid cancer.24-27 Given the cost ef-
fectiveness of  this non-invasive diagnostic tool, the inclu-
sion of  US analysis in routine follow-up of  breast cancer 
patients could be of  use in early detection of  thyroid me-
tastasis.
 
Ultrasound plays an important role in screening thyroid 
disease and making a differential diagnosis of  benign and 
malignant tumors. US features of  malignant thyroid nod-
ules in general and of  primary thyroid cancer and thy-
roid metastasis in particular are detailed elsewhere.28,29 
Although no single mentioned feature is decisive for 
malignant thyroid condition, presence of  a combination 
of  two or more of  these features increases the chances 
of  malignancy. In our study, two TM samples appeared 
as classical Primary Thyroid Cancer (PTC), while six pa-
tients showed heterogenous thyroid parenchyma with dif-
fuse calcifications without nodule, which is rare in TM 
conditions. Hence it becomes important to consider the 
possibility of  metastasis from elsewhere while diagnosing 
new thyroid masses in patients with a previous history 
of  malignancy. But it is difficult to differentiate between 
PTC and TM using US only. US guided FNAB/FNAC is 
of  value in such conditions whose accuracy for TM diag-
nosis from breast cancer is reportedly 90.8% to 91.2%.30 
In this regard, if  malignant cells are present in a thyroid 
FNAB and primary malignancy is not a consideration, 
then clinical history consideration with immunohisto-
chemical analysis is essential for accurate diagnosis.
 
The interval from a non-thyroid primary cancer diagnosis 
to TM diagnosis varies from a few months in aggressive 
malignancies, to many years in less aggressive condition, 
the median of  which was reported as 53 months.7 The 
same was found to be 76.5 months (median interval) in 
our study which is considerably higher than the reported 
value. Additional findings from our study reveal that the 
location of  primary source, including bilateral breast can-
cer condition, has no association with the probability of  
occurrence of  TM.
The metachronosity of  thyroid metastasis from breast 
cancer can be as long as 12 years from the diagnosis of  
the primary condition.31 In the present study, one of  our 
patients presented to the hospital with TM, more than 10 
years after she was diagnosed and treated for breast can-
cer. Such durations can be long enough to miss the past 
diagnosis/treatment of  malignant disease thus demand-
ing extra attention in the  history.
 
Numerous case reports have suggested that metastases 
to the thyroid gland are associated with poor prognosis, 
6,32 while others report that it does not seem to worsen 
the outcome when compared to other associated dis-
tant metastasis conditions.33 Few studies have assessed 
the effectiveness of  the therapy for TM from breast 
cancer condition. In agreement with Ishikawa et al., we 
found that thyroidectomy in an isolated TM condition, 
with controlled primary tumor, may result in prolonged 
disease-free survival with no difference in survival time 
amongst total and partial thyroidectomy.16 But, total thy-
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roidectomy was not effective in prolonging the life of  a 
patient with lung metastasis. Chemotherapy is the treat-
ment of  choice in such patients with widespread distant 
metastatic condition. In the present study chemothera-
py demonstrated shrinkage in the calcifications with a 
change in thyroid parenchyma from being heterogeneous 
to homogenous in four of  five distant metastasis pa-
tients. Hence, our supposition is that for the controlled 
primary tumor condition, with no associated relapse or 
distant metastasis, thyroidectomy may form the treatment 
of  choice in terms of  disease free survival; while for the 
widespread metastatic condition the TM may respond 
well to the administered chemotherapy, thus eliminating 
the need for thyroidectomy.
Due  to the rarity of  the condition, the present study is 
limited by the number of  patients assessed, which is not 
large enough to represent the population of  breast cancer 
patients with TM. A long term follow-up is also desirable 
to assess the treatment (thyroidectomy/chemotherapy) 
value in long-term disease free survival. Such studies are 
further warranted.
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Conclusion:
The infrequent, possibly metachronous and asymptom-
atic nature of  TM from extra-thyroid origin, makes it a 
challenging condition to be diagnosed in a clinical setting. 
With breast cancer being one of  the most common pri-
mary tumor exhibiting TM, a routine examination of  the 
thyroid gland is essential in such patients. In this regards, 
the US analysis may serve as the screening tool of  choice, 
owing to its non-invasive nature  and cost effectiveness. 
None the less, it is difficult to differentiate between PTC 
and TM using US alone, during which US guided FNAB/
FNAC is of  value in obtaining a more accurate diagnosis. 
Thyroidectomy, both partial and total, could be the treat-
ment of  choice in a controlled primary tumor condition, 
with no associated relapse or distant metastasis; while in 
a widespread metastatic condition the TM may respond 
well to the chemotherapy, and thus may eliminate the 
need for thyroidectomy.
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do not have IHC result 
because the patient 
underwent mastectomy 10 
years ago 
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was diagnosed 









10%)，Ki67（+，40%） 5 axillary lymph and left chest wall 
four cycles( GH regimens: Gemcitabine 
1.8g,d1; Herceptin 
6mg/kg,d1),than  Radiotherapy (DT 
50GY/25F); Leuprorelin Acetate For 








),，Ki67（+，40%） 3 axillary lymph 
 sequential therapy*4times 
(Pirarubicin,80mg,d1;CTX 
1.0,d1),and  Docetaxel 180mg d1;after that , 










21 axillary lymph 












5 right axillary lymph and left chest 
wall 








6 axillary lymph CTX0.6,Epi-ADM 90μg，5-FU 0.75 d1 
Complete Response 
6 Right 







4 axillary lymph 
TC regimens(docetaxel,130mg,d1; 
cyclophosphamide   0.75g,d1)(refuse 
Herceptin for economic reason) 
Complete Response 
 
